aiwell and Jikei University School of Medicine Sign Joint Research Agreement to Clarify Relationship Between Brain Tumor Gene Abnormalities and Prognosis
Biotech startup aiwell, a spin-off from the Institute of Science Tokyo, and Jikei University School of Medicine have partnered to research the correlation between gene abnormalities and prognosis in brain tumors using aiwell's proprietary 'aiwell IPA' protein analysis technology.
📋 Article Processing Timeline
- 📰 Published: April 22, 2026 at 20:32
- 🔍 Collected: April 23, 2026 at 00:02 (3h 29m after Published)
- 🤖 AI Analyzed: April 23, 2026 at 03:54 (3h 52m after Collected)
aiwell Inc. (Headquarters: Minato-ku, Tokyo; CEO: Hiroyuki Mabuchi), which promotes the social implementation of its protein biomarker discovery technology 'aiwell IPA,' and Jikei University School of Medicine (Location: Minato-ku, Tokyo; President: Senya Matsufuji) have signed a joint research agreement regarding the 'Relationship between gene abnormalities and prognosis in brain tumors.' This research, led by Professor Yasuharu Akazaki of the Department of Neurosurgery at Jikei University School of Medicine, aims to establish new diagnostic and therapeutic guidelines for refractory brain tumors.
### Background of the Joint Research
Malignant brain tumors remain one of the most difficult diseases to treat in modern medicine. It is known that even with the same diagnosis, prognosis and drug efficacy vary significantly depending on each patient's genetic mutations and protein expression patterns. While personalized medicine using gene panel testing is progressing, genetic information alone cannot fully grasp the dynamics of proteins actually functioning in the body. Therefore, more precise prognosis prediction and identification of therapeutic targets have been sought.
### Overview and Objectives of the Research
This research merges the advanced clinical insights and precious brain tumor specimens held by Jikei University with the protein biomarker discovery technology 'aiwell IPA' developed by aiwell. 'aiwell IPA' is a proprietary technology that comprehensively visualizes thousands of protein states from trace samples and extracts disease-related protein fluctuations with high precision.
1. **Analysis Targets:** Tumor tissue collected during brain tumor surgery and tumor cells derived from it.
2. **Technical Approach:** Using aiwell IPA to comprehensively analyze protein fluctuations associated with specific genetic abnormalities, aiming to clarify the molecular basis involved in the efficacy of immunotherapy.
3. **Objective:** To identify new biomarkers that influence prognosis and build a foundation for 'precision medicine' where the optimal treatment can be selected for each individual patient.
### Expected Results
- **Highly Accurate Prognosis Prediction:** Predicting recurrence risks and survival periods more accurately at the time of diagnosis.
- **Optimization of Treatment:** Supporting the selection of highly efficient drugs, contributing to reduced side effects and improved Quality of Life (QOL).
- **Discovery of New Drug Targets:** Identifying specific proteins involved in worsening prognosis to pave the way for next-generation drug development.
### Comments from Organizations
**Hiroyuki Mabuchi, CEO of aiwell Inc.**
'This joint research integrates Jikei University's long-accumulated clinical specimens and insights into immunotherapy with our protein biomarker discovery technology, aiwell IPA. By comprehensively analyzing the state of functioning proteins that cannot be fully captured by genetic information alone, we believe we can contribute to identifying biomarkers that determine the effect of immunotherapy and new therapeutic targets.'
**Professor Yasuharu Akazaki, Department of Neurosurgery, Jikei University School of Medicine**
'We have been conducting clinical research on immunotherapy using "tumor-fused dendritic cells" and have accumulated frozen tumor cells and peripheral blood mononuclear cells along with clinical data. In this research, we will use these resources to explore prognosis prediction biomarkers and therapeutic targets for immunotherapy against malignant brain tumors in collaboration with aiwell.'
### About aiwell Inc.
aiwell is a deep-tech biotech venture originating from the Institute of Science Tokyo. Based on its proprietary proteomics technology, it provides 'aiwell IPA,' a platform for rapidly searching for protein biomarkers that visualize health status and disease risk signs from slight protein fluctuations in the blood. By merging AI image analysis and mass spectrometry, aiwell IPA has significantly streamlined biomarker discovery, which previously required significant time and cost. Its applications are expanding into livestock, agriculture, and food sectors. aiwell has established the Proteomics Innovation Center (PIC) in Shin-Kawasaki to promote the social implementation of health prediction and disease prevention through protein analysis.
### Background of the Joint Research
Malignant brain tumors remain one of the most difficult diseases to treat in modern medicine. It is known that even with the same diagnosis, prognosis and drug efficacy vary significantly depending on each patient's genetic mutations and protein expression patterns. While personalized medicine using gene panel testing is progressing, genetic information alone cannot fully grasp the dynamics of proteins actually functioning in the body. Therefore, more precise prognosis prediction and identification of therapeutic targets have been sought.
### Overview and Objectives of the Research
This research merges the advanced clinical insights and precious brain tumor specimens held by Jikei University with the protein biomarker discovery technology 'aiwell IPA' developed by aiwell. 'aiwell IPA' is a proprietary technology that comprehensively visualizes thousands of protein states from trace samples and extracts disease-related protein fluctuations with high precision.
1. **Analysis Targets:** Tumor tissue collected during brain tumor surgery and tumor cells derived from it.
2. **Technical Approach:** Using aiwell IPA to comprehensively analyze protein fluctuations associated with specific genetic abnormalities, aiming to clarify the molecular basis involved in the efficacy of immunotherapy.
3. **Objective:** To identify new biomarkers that influence prognosis and build a foundation for 'precision medicine' where the optimal treatment can be selected for each individual patient.
### Expected Results
- **Highly Accurate Prognosis Prediction:** Predicting recurrence risks and survival periods more accurately at the time of diagnosis.
- **Optimization of Treatment:** Supporting the selection of highly efficient drugs, contributing to reduced side effects and improved Quality of Life (QOL).
- **Discovery of New Drug Targets:** Identifying specific proteins involved in worsening prognosis to pave the way for next-generation drug development.
### Comments from Organizations
**Hiroyuki Mabuchi, CEO of aiwell Inc.**
'This joint research integrates Jikei University's long-accumulated clinical specimens and insights into immunotherapy with our protein biomarker discovery technology, aiwell IPA. By comprehensively analyzing the state of functioning proteins that cannot be fully captured by genetic information alone, we believe we can contribute to identifying biomarkers that determine the effect of immunotherapy and new therapeutic targets.'
**Professor Yasuharu Akazaki, Department of Neurosurgery, Jikei University School of Medicine**
'We have been conducting clinical research on immunotherapy using "tumor-fused dendritic cells" and have accumulated frozen tumor cells and peripheral blood mononuclear cells along with clinical data. In this research, we will use these resources to explore prognosis prediction biomarkers and therapeutic targets for immunotherapy against malignant brain tumors in collaboration with aiwell.'
### About aiwell Inc.
aiwell is a deep-tech biotech venture originating from the Institute of Science Tokyo. Based on its proprietary proteomics technology, it provides 'aiwell IPA,' a platform for rapidly searching for protein biomarkers that visualize health status and disease risk signs from slight protein fluctuations in the blood. By merging AI image analysis and mass spectrometry, aiwell IPA has significantly streamlined biomarker discovery, which previously required significant time and cost. Its applications are expanding into livestock, agriculture, and food sectors. aiwell has established the Proteomics Innovation Center (PIC) in Shin-Kawasaki to promote the social implementation of health prediction and disease prevention through protein analysis.